Intellia Therapeutics (NASDAQ:NTLA) will be announcing its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. Intellia Therapeutics had a negative return on equity of 33.03% and a negative net margin of 242.65%. The firm had revenue of $11.10 million during the quarter, compared to analyst estimates of $7.15 million. During the same period in the previous year, the company earned ($0.52) EPS. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. On average, analysts expect Intellia Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
NTLA opened at $11.05 on Friday. The business has a 50 day moving average price of $12.75 and a 200 day moving average price of $15.23. Intellia Therapeutics has a twelve month low of $10.26 and a twelve month high of $20.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99. The firm has a market cap of $545.45 million, a P/E ratio of -5.58 and a beta of 2.70.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
See Also: Overbought
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.